The company said it has provided relevant information as requested to help the DCGI determine the most appropriate use of molnupiravir in India.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/34ofngx
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGI
https://ift.tt/eA8V8J
No comments:
Post a Comment